Page last updated: 2024-08-24

ibandronic acid and pamidronate

ibandronic acid has been researched along with pamidronate in 86 studies

Research

Studies (86)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (9.30)	18.2507
2000's	45 (52.33)	29.6817
2010's	30 (34.88)	24.3611
2020's	3 (3.49)	2.80

Authors

Authors	Studies
Cieslak, JA; Coates, RM; Fukura, S; Koohang, A; Lea, CR; Lee, HJ; Loftus, TC; Martin, MB; Matsumura, Y; Oldfield, E; Sagami, H; Sanders, JM; Sengupta, S; Szabo, CM	1
Martin, MB; Oldfield, E; Szabo, CM	1
Burzynska, A; Croft, SL; de Luca-Fradley, K; Grimley, JS; Kafarski, P; Kendrick, H; Lewis, JC; Martin, MB; Meints, GA; Oldfield, E; Olsen, JR; Sanders, JM; Van Brussel, EM	1
Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L	1
Gossman, W; Oldfield, E	1
Burzynska, A; Gómez, AO; González-Pacanowska, D; Kafarski, P; Mao, J; Meints, GA; Oldfield, E; Sanders, JM; Van Brussel, EM	1
Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H	1
Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G	1
Hall, P; Hudock, MP; Leon, A; Liu, L; Morita, CT; Oldfield, E; Puan, KJ; Studer, D; Yang, Y; Yin, F	1
Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG	1
Lombardo, F; Obach, RS; Waters, NJ	1
Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Almeida Paz, FA; Barbosa, JS; Braga, SS	1
Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K	1
Baumgartner, G; Blind, E; Pecherstorfer, M; Raue, F; Schilling, T; Ziegler, R; Zimmer-Roth, I	1
Collin, P; Fleisch, H; Guenther, HL; Martin, TJ; Sahni, M	1
Burckhardt, P; Fioroni, P; Juillerat, L; Leuenberger, P; Ludwig, H; Markert, M; Pecherstorfer, M; Sauty, A; Thiebaud, D; Zimmer-Roth, I	1
Chilton, KM; Coxon, FP; Lawry, J; Rogers, MJ; Russell, RG; Smith, MO; Suri, S	1
Boissier, S; Clezardin, P; Cuzin, B; Delmas, PD; Ebetino, FH; Frappart, L; Magnetto, S	1
Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD	1
Cohen, L; Löwik, C; Papapoulos, S; Pieterman, E; van Beek, E	1
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP	1
Horn, E; Jilch, R; Keck, AV; Pecherstorfer, M; Sauty, A; Thiebaud, D; Zimmer-Roth, I	1
Bauer, E; Feurle, J; Kunzmann, V; Tony, HP; Weissinger, F; Wilhelm, M	1
Body, JJ	1
Body, JJ; Fromigue, O; Lagneaux, L	1
Body, JJ; Fromigué, O	1
Berenson, JR	1
de la Fuente, J; Goldman, JM; Karkantaris, C; Meletis, J; Palermos, J; Rahemtulla, A; Terpos, E; Vaiopoulos, G; Viniou, N; Voskaridou, E; Yataganas, X	1
Bergström, B; Pecherstorfer, M; Rizzoli, R; Steinhauer, EU; Wetterwald, M	1
Bjarnason, NH	1
Adami, S; Crepaldi, G; Filipponi, P; Sartori, L	1
Cundy, T; King, A; Wheadon, L	1
Berenson, J; Hirschberg, R	1
Boos, J; Lanvers-Kaminsky, C; Vorotnjak, M	1
Harvey, HA	1
Khuri, F; Saba, N	1
Coleman, RE	1
Balla, J	1
Lugassy, G	1
Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP	2
Lipton, A	1
Gordon, DH	1
Franke, HR; Verdijk, R; Vermes, I; Wolbers, F	1
Langdahl, B; Mosekilde, L; Vestergaard, P	1
Armamento-Villareal, R; Civitelli, R; Napoli, N	1
Clemons, M; Cole, DE; Dranitsaris, G; Ooi, W	1
McKeage, K; Plosker, GL	1
Bauss, F; Haiker, M; Künkele, KP; Lühe, A; Pfister, T; Schad, K; Suter, L; Zihlmann, C	1
Baldini, E; Barni, S; Berto, P; Cortesi, E; Dauria, G; Schivazappa, C	1
Kalogeropoulou, C; Kardamakis, D; Vassiliou, V	1
Bao, C; Gao, Y; Hu, J; Liu, X; Zou, S	1
Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K	1
Al-Nawas, B; Brüllmann, D; Gauss, L; Kämmerer, P; Klein, MO; Pabst, A; Walter, C; Ziebart, T	1
Henry, C; Jahnke, W	1
Lindor, KD; Petz, JL; Silveira, MG; Treeprasertsuk, S	1
Hatzopoulos, A; Heras, P; Heras, V; Karagiannis, S; Kritikos, K; Kritikos, N	1
Al-Nawas, B; Klein, M; Pabst, A; Walter, C; Ziebart, T	1
Brüllmann, DD; d'Hoedt, B; Klein, MO; Lehmann, KM; Pabst, A; Ziebart, T	1
Al-Nawas, B; Koch, FP; Pabst, AM; Taylor, KY; Walter, C; Ziebart, T	1
Cevreska, L; Jovanovic, R; Karanfilski, O; Pavkovic, M; Petrushevska, G; Stankovic, S; Stojanovic, A	1
Chambers, SA; Clarke, A; Wolman, R	1
Bissinger, O; Ehrenfeld, M; Kolk, A; Mast, G; Mücke, T; Otto, S; Pautke, C; Schreyer, C; Stürzenbaum, SR; Wolff, KD	1
Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W	1
Chen, M; Chen, Y; Chen, Z; Liu, Y; Zhu, Y	1
Achel, DG; Alcaraz, M; Alcaraz-Saura, M; Olivares, A	1
Ben-Aharon, I; Rizel, S; Shpilberg, O; Stemmer, SM; Sulkes, A; Vidal, L; Yerushalmi, R	1
Brown, J; Fullarton, JR; Palmieri, C	1
Dong, R; Li, J; Liu, WX; Wang, XX; Zhang, J; Zhao, SY	1
Alegre, A; Bailén, A; Giraldo, P; Gironella, M	1
Hagelauer, N; Pabst, AM; Ulbrich, H; Walter, C; Ziebart, T	1
Felsenberg, D; Gabbert, TI; Hoffmeister, B	1
Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G	1
De Luna-Bertos, E; García-Martínez, O; Manzano-Moreno, FJ; Ramos-Torrecillas, J; Ruiz, C	1
Curtis, D; Lu, Y; Qiao, D; Wang, Z; Wen, X; Yao, Y; Zhao, H	1
Jacobs, C; Krüger, M; Pabst, AM; Sagheb, K; Walter, C; Ziebart, T	1
Mészaros, Á; Veszelyné Kotán, E	2
González, R; López-Posadas, R; Martínez-Augustin, O; Mascaraque, C; Sánchez de Medina, F; Suárez, MD; Zarzuelo, A	1
Abduljabbar, T; Gholamiazizi, E; Javed, F; Kellesarian, SV; Malmstrom, H; Romanos, GE; Vohra, F	1
Ermer, MA; Kottmann, SC; Otten, JE; Pelz, K; Poxleitner, P; Wittmer, A	1
Aoki, K; Nakamura, M; Saito, N; Ueda, K; Yamamoto, Y; Yudasaka, M; Zhang, M	1
Chen, Y; Huang, Y; Xiao, Y	1

Reviews

24 review(s) available for ibandronic acid and pamidronate

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Bisphosphonates, Old Friends of Bones and New Trends in Clinics. Journal of medicinal chemistry, 2021, 02-11, Volume: 64, Issue:3 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans	2021
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:12 Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Multiple Myeloma; Pain; Pamidronate	1998
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid	2000
Current and future directions in medical therapy: hypercalcemia. Cancer, 2000, Jun-15, Volume: 88, Issue:12 Suppl Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid	2000
Treatment of hypercalcemia of malignancy with bisphosphonates. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 21 Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid	2002
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. Aging clinical and experimental research, 2003, Volume: 15, Issue:4 Topics: Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Zoledronic Acid	2003
Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:5 Topics: Alkaline Phosphatase; Audiometry, Pure-Tone; Biomarkers; Biopsy; Bone Conduction; Bone Density; Bone Resorption; Child; Collagen; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Osteitis Deformans; Pamidronate; Pelvic Bones; Peptides; Radiography; Spine; Treatment Outcome	2004
Safety and convenience of a 15-minute infusion of zoledronic acid. The oncologist, 2004, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid	2004
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 12 Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid	2004
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications. Oncology, 2005, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid	2005
Bisphosphonates in breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:5 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Staging; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid	2005
New therapeutic agents for the treatment of bone diseases. Expert opinion on biological therapy, 2005, Volume: 5, Issue:6 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2005
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clinical breast cancer, 2005, Volume: 6, Issue:2 Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2005
Fracture prevention in postmenopausal women. Clinical evidence, 2006, Issue:15 Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D	2006
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. PharmacoEconomics, 2008, Volume: 26, Issue:3 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid	2008
Treatment of lumbar pars interarticularis stress injuries in athletes with intravenous bisphosphonates: five case studies. Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, 2011, Volume: 21, Issue:2 Topics: Adolescent; Athletic Injuries; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Stress; Humans; Ibandronic Acid; Infusions, Intravenous; Lumbar Vertebrae; Male; Off-Label Use; Pamidronate; Retrospective Studies; Treatment Outcome; Young Adult	2011
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis. PloS one, 2013, Volume: 8, Issue:8 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Female; Humans; Ibandronic Acid; Pamidronate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Risedronic Acid; Risk; Treatment Outcome	2013
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24 Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2013
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. European journal of haematology, 2014, Volume: 92, Issue:3 Topics: Antineoplastic Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Ibandronic Acid; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid	2014
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. Cancer treatment reviews, 2015, Volume: 41, Issue:2 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid	2015
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. The oncologist, 2015, Volume: 20, Issue:4 Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid	2015
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid	2016
Does Local Ibandronate and/or Pamidronate Delivery Enhance Osseointegration? A Systematic Review. Journal of prosthodontics : official journal of the American College of Prosthodontists, 2018, Volume: 27, Issue:3 Topics: Administration, Topical; Bone Density Conservation Agents; Humans; Ibandronic Acid; Osseointegration; Pamidronate	2018

Trials

6 trial(s) available for ibandronic acid and pamidronate

Article	Year
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone, 1996, Volume: 18, Issue:2 Topics: Aged; Aged, 80 and over; Bone Resorption; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Interleukin-1; Interleukin-6; Male; Middle Aged; Neoplasms; Pamidronate; Tumor Necrosis Factor-alpha	1996
Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Lectins, C-Type; Lymphocyte Subsets; Male; Middle Aged; Pamidronate; Prospective Studies; Tumor Necrosis Factor-alpha	2000
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. European journal of haematology, 2003, Volume: 70, Issue:1 Topics: Acid Phosphatase; Aged; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Interleukin-6; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteogenesis; Pamidronate; Peptides; Tartrate-Resistant Acid Phosphatase	2003
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2003, Volume: 11, Issue:8 Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Neoplasms; Pamidronate; Treatment Outcome	2003
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast cancer research and treatment, 2008, Volume: 108, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Pain; Palliative Care; Pamidronate	2008
A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain. American journal of therapeutics, 2011, Volume: 18, Issue:5 Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Lung Neoplasms; Male; Middle Aged; Pain; Pamidronate; Quality of Life	2011

Other Studies

56 other study(ies) available for ibandronic acid and pamidronate

Article	Year
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. Journal of medicinal chemistry, 2002, May-23, Volume: 45, Issue:11 Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Molecular; Organophosphates; Quantitative Structure-Activity Relationship; Recombinant Proteins	2002
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14 Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats	2002
Activity of bisphosphonates against Trypanosoma brucei rhodesiense. Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14 Topics: Animals; Crystallography, X-Ray; Diphosphonates; Humans; Lethal Dose 50; Models, Molecular; Quantitative Structure-Activity Relationship; Quantum Theory; Trypanocidal Agents; Trypanosoma brucei rhodesiense; Tumor Cells, Cultured	2002
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). Journal of medicinal chemistry, 2002, Aug-15, Volume: 45, Issue:17 Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid	2002
Quantitative structure--activity relations for gammadelta T cell activation by phosphoantigens. Journal of medicinal chemistry, 2002, Oct-24, Volume: 45, Issue:22 Topics: Antigens, Bacterial; Lymphocyte Activation; Models, Molecular; Phosphoproteins; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes	2002
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. Journal of medicinal chemistry, 2003, Nov-20, Volume: 46, Issue:24 Topics: Animals; Crystallography, X-Ray; Dimethylallyltranstransferase; Diphosphonates; Imidazoles; Leishmania major; Models, Molecular; Picolinic Acids; Pyridines; Quantitative Structure-Activity Relationship; Zoledronic Acid	2003
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. Journal of medicinal chemistry, 2004, Jan-15, Volume: 47, Issue:2 Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha	2004
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. Journal of medicinal chemistry, 2005, May-05, Volume: 48, Issue:9 Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis	2005
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin. Journal of medicinal chemistry, 2006, Dec-14, Volume: 49, Issue:25 Topics: Anti-Bacterial Agents; Cluster Analysis; Diphosphonates; Drug Synergism; Escherichia coli K12; Fosfomycin; Gene Expression; Geranyltranstransferase; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quantitative Structure-Activity Relationship; Terpenes	2006
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. Journal of medicinal chemistry, 2008, Apr-10, Volume: 51, Issue:7 Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. Journal of medicinal chemistry, 2008, Sep-25, Volume: 51, Issue:18 Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship	2008
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1991, Volume: 6, Issue:9 Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Ibandronic Acid; Injections, Intravenous; Osteoclasts; Pamidronate; Rats; Retinoids; Risedronic Acid; Spectrophotometry, Atomic; Tetracycline; Thyroxine	1991
Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. The Journal of clinical endocrinology and metabolism, 1994, Volume: 78, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Life Expectancy; Male; Middle Aged; Neoplasms; Pamidronate; Parathyroid Hormone-Related Protein; Proteins; Survival Rate	1994
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. The Journal of clinical investigation, 1993, Volume: 91, Issue:5 Topics: Alendronate; Animals; Animals, Newborn; Bone Resorption; Cell Line; Cells, Cultured; Clodronic Acid; Culture Media, Conditioned; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Ibandronic Acid; Kinetics; Osteoblasts; Pamidronate; Parathyroid Hormone; Rats; Rats, Wistar; Time Factors	1993
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1996, Volume: 11, Issue:10 Topics: Alendronate; Animals; Apoptosis; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Nucleus; Cells, Cultured; Diphosphonates; DNA; DNA Fragmentation; Electrophoresis, Polyacrylamide Gel; Ibandronic Acid; Macrophages; Mice; Necrosis; Nitric Oxide; Pamidronate; Protein Biosynthesis	1996
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer research, 1997, Sep-15, Volume: 57, Issue:18 Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhesion Molecules; Clodronic Acid; Diphosphonates; Extracellular Matrix; Female; Humans; Ibandronic Acid; In Vitro Techniques; Integrins; Male; Neoplasm Metastasis; Osteoblasts; Pamidronate; Prostatic Neoplasms; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured	1997
Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochemical and biophysical research communications, 1999, Feb-16, Volume: 255, Issue:2 Topics: Animals; Bone Resorption; Brain; Carbon-Carbon Double Bond Isomerases; Cattle; Clodronic Acid; Dimethylallyltranstransferase; Diphosphonates; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Hemiterpenes; Ibandronic Acid; Mice; Multienzyme Complexes; Nitrogen; Pamidronate	1999
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood, 2000, Jul-15, Volume: 96, Issue:2 Topics: Alendronate; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Bone Marrow Cells; Cell Division; Cell Survival; Cytotoxicity, Immunologic; Diphosphonates; Humans; Ibandronic Acid; Interferon-gamma; Interleukin-2; Kinetics; Lectins, C-Type; Lymphocyte Activation; Multiple Myeloma; Pamidronate; Plasma Cells; Receptors, Interleukin-2; T-Lymphocytes; Tumor Cells, Cultured	2000
Bisphosphonates induce breast cancer cell death in vitro. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:11 Topics: Amino Acid Chloromethyl Ketones; Annexins; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase Inhibitors; Caspases; Cell Death; Cell Nucleus; Clodronic Acid; Cysteine Proteinase Inhibitors; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Imidazoles; Kinetics; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid	2000
Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. Journal of endocrinological investigation, 2002, Volume: 25, Issue:6 Topics: Adult; Aged; Alkaline Phosphatase; Cell Differentiation; Cell Division; Cell Survival; Cells, Cultured; Clodronic Acid; Collagen Type I; Culture Media; Culture Media, Serum-Free; Diphosphonates; Fetal Blood; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoblasts; Pamidronate; Zoledronic Acid	2002
Bisphosphonates in children with bone diseases. The New England journal of medicine, 2003, Nov-20, Volume: 349, Issue:21 Topics: Bone Density; Bone Resorption; Child; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Male; Osteopetrosis; Pamidronate	2003
In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. Anti-cancer drugs, 2004, Volume: 15, Issue:8 Topics: Alendronate; Apoptosis; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Diphosphonates; Drug Screening Assays, Antitumor; Germany; Humans; Ibandronic Acid; Imidazoles; Neuroblastoma; Pamidronate; Time Factors; Zoledronic Acid	2004
The issue of renal safety of zoledronic acid from a nephrologist's point of view. The oncologist, 2005, Volume: 10, Issue:5 Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid	2005
"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe. The oncologist, 2005, Volume: 10, Issue:5 Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid	2005
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2005, Volume: 13, Issue:12 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Metastasis; Pamidronate; Quality of Life; State Medicine; United Kingdom; Zoledronic Acid	2005
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clinical therapeutics, 2005, Volume: 27, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Pamidronate; Quality-Adjusted Life Years; United Kingdom; Zoledronic Acid	2005
Differential effects of bisphosphonates on breast cancer cell lines. Cancer letters, 2007, Feb-08, Volume: 246, Issue:1-2 Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid	2007
Use of intravenous bisphosphonates in osteoporosis. Current osteoporosis reports, 2007, Volume: 5, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Patient Compliance; Zoledronic Acid	2007
Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicology in vitro : an international journal published in association with BIBRA, 2008, Volume: 22, Issue:4 Topics: Animals; Bone Density Conservation Agents; Cell Line; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Geranyltranstransferase; Humans; Ibandronic Acid; Imidazoles; Inhibitory Concentration 50; Kidney; Male; Pamidronate; Rats; Rats, Sprague-Dawley; RNA, Messenger; Zoledronic Acid	2008
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies]. Recenti progressi in medicina, 2008, Volume: 99, Issue:1 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Pamidronate; Zoledronic Acid	2008
Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates. Journal of surgical oncology, 2008, Dec-01, Volume: 98, Issue:7 Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Osteogenesis; Pain Measurement; Pamidronate; Radiotherapy, Adjuvant; Zoledronic Acid	2008
The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials, 2009, Volume: 30, Issue:9 Topics: Absorptiometry, Photon; Animals; Biomechanical Phenomena; Bone Density; Coated Materials, Biocompatible; Diphosphonates; Durapatite; Female; Ibandronic Acid; Imidazoles; Implants, Experimental; Microscopy, Electron, Scanning; Ovariectomy; Pamidronate; Rats; Rats, Sprague-Dawley; Surface Properties; Tibia; Titanium; X-Ray Microtomography; Zoledronic Acid	2009
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2009
Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clinical oral investigations, 2011, Volume: 15, Issue:1 Topics: Analysis of Variance; Apoptosis; Bone Density Conservation Agents; Cell Movement; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Humans; Ibandronic Acid; Imidazoles; Leukocytes, Mononuclear; Neovascularization, Physiologic; Pamidronate; Statistics, Nonparametric; Stem Cells; Umbilical Veins; Zoledronic Acid	2011
An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem, 2010, May-03, Volume: 5, Issue:5 Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid	2010
Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. American journal of therapeutics, 2011, Volume: 18, Issue:5 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Liver Cirrhosis, Biliary; Male; Middle Aged; Osteoporosis; Pamidronate; Retrospective Studies; Zoledronic Acid	2011
Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral diseases, 2011, Volume: 17, Issue:2 Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Movement; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Fibroblasts; Fluoresceins; Fluorescent Dyes; Humans; Ibandronic Acid; Imidazoles; In Situ Nick-End Labeling; Nitrogen; Osteoblasts; Pamidronate; Umbilical Veins; Zoledronic Acid	2011
Counting touching cell nuclei using fast ellipse detection to assess in vitro cell characteristics: a feasibility study. Clinical oral investigations, 2012, Volume: 16, Issue:1 Topics: Algorithms; Aluminum Silicates; Biocompatible Materials; Bone Density Conservation Agents; Cell Count; Cell Culture Techniques; Cell Nucleus; Cell Proliferation; Cell Size; Ceramics; Diphosphonates; Endothelial Cells; False Negative Reactions; False Positive Reactions; Feasibility Studies; Fibroblasts; Fluorescent Dyes; Humans; Ibandronic Acid; Image Processing, Computer-Assisted; Microscopy; Osteogenesis; Pamidronate; Potassium Compounds; Software; Stem Cells; Time Factors; Titanium	2012
The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study. Clinical oral investigations, 2012, Volume: 16, Issue:1 Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Clodronic Acid; Coloring Agents; Diphosphonates; Fluoresceins; Fluorescent Dyes; Humans; Ibandronic Acid; Imidazoles; In Situ Nick-End Labeling; Keratinocytes; Mouth Mucosa; Pamidronate; Tetrazolium Salts; Thiazoles; Zoledronic Acid	2012
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates. Prilozi, 2010, Volume: 31, Issue:2 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Middle Aged; Multiple Myeloma; Pamidronate	2010
Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2012, Volume: 40, Issue:7 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Maxillary Diseases; Maxillary Sinusitis; Oroantral Fistula; Pamidronate; Radiography, Panoramic; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid	2012
Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clinical oral investigations, 2013, Volume: 17, Issue:1 Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid	2013
[Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection]. Se pu = Chinese journal of chromatography, 2012, Volume: 30, Issue:4 Topics: Alendronate; Chromatography, Ion Exchange; Diphosphonates; Electrochemical Techniques; Etidronic Acid; Humans; Ibandronic Acid; Pamidronate; Risedronic Acid	2012
Effects of bisphosphonates in combination with ionizing radiation and antioxidants on the growth of prostate and melanoma cells lines. Anticancer research, 2013, Volume: 33, Issue:8 Topics: Animals; Antioxidants; Apigenin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Melanoma; Mice; Pamidronate; Prostatic Neoplasms; Radiation, Ionizing; Skin Neoplasms; Zoledronic Acid	2013
[Effect of pamidronate and ibandronate on orthodontic root resorption in rats]. Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, 2013, Volume: 48, Issue:9 Topics: Animals; Bone Density Conservation Agents; Cell Count; Diphosphonates; Female; Ibandronic Acid; Osteoclasts; Pamidronate; Random Allocation; RANK Ligand; Rats; Rats, Wistar; Root Resorption; Tooth Movement Techniques	2013
In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes. Clinical oral investigations, 2015, Volume: 19, Issue:1 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Chemotaxis; Clodronic Acid; Diphosphonates; Flow Cytometry; Granulocytes; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Neutrophils; Pamidronate; Phagocytosis; Respiratory Burst; Zoledronic Acid	2015
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid	2015
High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2015, Volume: 43, Issue:3 Topics: Alendronate; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Coloring Agents; Diphosphonates; Dose-Response Relationship, Drug; Flow Cytometry; G1 Phase; Humans; Ibandronic Acid; Necrosis; Osteoblasts; Pamidronate; Resting Phase, Cell Cycle; Spectrophotometry; Tetrazolium Salts; Thiazoles; Time Factors	2015
The influence of geranylgeraniol on human oral keratinocytes after bisphosphonate treatment: An in vitro study. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2015, Volume: 43, Issue:5 Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Diterpenes; Humans; Ibandronic Acid; Imidazoles; Keratinocytes; Mouth Mucosa; Pamidronate; Zoledronic Acid	2015
[Bisphosphonate use and related pharmaceutical issues II]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid	2016
The Bisphosphonate Pamidronate is an Intestinal Antiinflammatory Agent in Rat and Mouse Experimental Colitis. Inflammatory bowel diseases, 2016, Volume: 22, Issue:11 Topics: Alendronate; Animals; Anti-Inflammatory Agents; Colitis; Dextran Sulfate; Diphosphonates; Ibandronic Acid; Immunologic Factors; Intestinal Mucosa; Mice; Pamidronate; Rats; T-Lymphocytes; Trinitrobenzenesulfonic Acid	2016
In Vitro Investigation of the Antimicrobial Effect of Three Bisphosphonates Against Different Bacterial Strains. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2018, Volume: 76, Issue:3 Topics: Anti-Infective Agents; Diphosphonates; Gram-Negative Bacteria; Gram-Positive Bacteria; Ibandronic Acid; Microbial Sensitivity Tests; Microbiota; Mouth; Pamidronate; Zoledronic Acid	2018
Bisphosphonate type-dependent cell viability suppressive effects of carbon nanohorn-calcium phosphate-bisphosphonate nanocomposites. Biomaterials science, 2022, Oct-11, Volume: 10, Issue:20 Topics: Animals; Bone Neoplasms; Bone Resorption; Calcium Phosphates; Carbon; Cell Survival; Diphosphonates; Drug Carriers; Ibandronic Acid; Mice; Nanocomposites; Osteoclasts; Pamidronate; Reactive Oxygen Species; Zoledronic Acid	2022
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. Scientific reports, 2023, 07-05, Volume: 13, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Femur; Humans; Ibandronic Acid; Osteoporosis; Pamidronate; Pharmaceutical Preparations; Risedronic Acid	2023